Metric Finance
LearnFAQ
LearnFAQ

Learn / PHAR

NASDAQ: PHAR

Pharming Group N.V. (PHAR) stock, explained like you're 5

Pharming Group N.V. trades on the Nasdaq under the ticker PHAR. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 691 million dollars.

Ticker
PHAR
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 691 million dollars

Is Pharming Group N.V. a small, medium or large cap company?

No. Pharming Group N.V. is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 691 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Pharming Group N.V. makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves PHAR stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Pharming Group (PHAR) Stock Price, News & Analysis (MarketBeat)
  • Pharming Group N.V. (PHARM.AS) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Spleen size fell in 10 of 11 trial participants taking an immune disease drug (Stock Titan)
  • Pharming Group N.V. (PHAR) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Discipline and Rules Based Execution in PHAR Response (Stock Traders Daily)

Follow PHAR in your daily brief

Each trading day at 5 PM ET we post what happened to Pharming Group N.V. and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow PHAR

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Pharming Group N.V. stock

What does Pharming Group N.V. do?

Pharming Group N.V. trades on the Nasdaq under the ticker PHAR. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 691 million dollars.

What is the ticker symbol for Pharming Group N.V.?

Pharming Group N.V. trades under the ticker PHAR on the Nasdaq.

What is Pharming Group N.V.'s market cap?

Pharming Group N.V. is a small cap stock with a market cap of about 691 million dollars.

How does Pharming Group N.V. make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves PHAR stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow PHAR stock every day?

Add PHAR to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow PHAR daily

A free brief on Pharming Group N.V. and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare PHAR: PHAR vs NVS, PHAR vs AZN, PHAR vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed